Population pharmacokinetic model development and its relationship with adverse events of oxcarbazepine in adult patients with epilepsy
Abstract This study aimed to develop a pharmacokinetic (PK) model of oxcarbazepine (OXC) and analyse the relationship between monohydroxylated derivative (MHD), an active metabolite of OXC, and the adverse events of OXC. We obtained 711 OXC samples from 618 patients with epilepsy who were enrolled i...
Guardado en:
Autores principales: | Yoonhyuk Jang, Seonghae Yoon, Tae-Joon Kim, SeungHwan Lee, Kyung-Sang Yu, In-Jin Jang, Kon Chu, Sang Kun Lee |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/6c0150e2099e43f5a9056c9e990cf932 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
High albumin level is a predictor of favorable response to immunotherapy in autoimmune encephalitis
por: Yoonhyuk Jang, et al.
Publicado: (2018) -
AS3MT Polymorphism: A Risk Factor for Epilepsy Susceptibility and Adverse Drug Reactions to Valproic Acid and Oxcarbazepine Treatment in Children From South China
por: Xiaomei Fan, et al.
Publicado: (2021) -
Efficacy and safety of oxcarbazepine in the treatment of children with epilepsy: a meta-analysis of randomized controlled trials
por: Geng H, et al.
Publicado: (2017) -
Proteins related to ictogenesis and seizure clustering in chronic epilepsy
por: Woo-Jin Lee, et al.
Publicado: (2021) -
The necessary conduct: Exploratory multiregional clinical trials in East Asia
por: Inseung Jeon, et al.
Publicado: (2021)